Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Histologically confirmed locally confined adenocarcinoma of the prostate with primary tumors confined to the prostate, clinical stage T1b,1c, 2a or 2b.~* Negative nodes evaluated by imaging methods (classified in the study as NX) or by surgical sampling (classified in the study as N0).~* Karnofsky performance status ≥ 70.~* PSA is mandatory, must be ≤ 20)~* No prior hormonal therapy, radiation or chemotherapy.~* Prior finasteride for prostate hypertrophy allowed if discontinued at least 60 days prior to randomization.~* Prior testosterone administration allowed if at least 90 days elapsed since last administration.~* No evidence of distant metastasis or other synchronous primary. Patients with prior invasive malignancy who were disease free for at least 5 years could be eligible with pre-randomization approval by the study chairman.~* Treatment begins within 21 days after randomization.~* Patients signs a study-specific informed consent form.~* Alanine Aminotransferase (ALT) within 2x upper normal limits.~Exclusion criteria:~* Stage T1a or ≥ T2c disease.~* Lymph node involvement (N1 - N3).~* Evidence of distant metastasis. (M1)~* PSA \> 20.~* Radical surgery or cryosurgery for carcinoma of the prostate, previous irradiation, antiandrogen therapy or chemotherapy.~* Previous or concurrent cancers other than basal cell or squamous cell skin carcinoma.~Patients with squamous cell carcinomas required to be NED (no evidence of disease) for a minimum of two years prior to study entry.~* Major medical or psychiatric illness which, in the investigator's opinion, would prevent completion of treatment and would interfere with follow-up.~* Karnofsky performance status of \< 70.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neoadjuvant TAS + RT (Type: EXPERIMENTAL): Neoadjuvant total androgen suppression (TAS) - Flutamide and Zoladex or Lupron - two months before and during radiation therapy.
- Radiation therapy alone (Type: OTHER): Radiation therapy alone

Based on this trial design, predict the completion outcome and termination type (if applicable).